Staxyn Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Staxyn, and what generic alternatives are available?
Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has fifty-three patent family members in thirty-eight countries.
The generic ingredient in STAXYN is vardenafil hydrochloride. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Staxyn
A generic version of Staxyn was approved as vardenafil hydrochloride by TEVA PHARMS on May 3rd, 2012.
Summary for Staxyn
International Patents: | 53 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Patent Applications: | 6 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for Staxyn |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for Staxyn |
What excipients (inactive ingredients) are in Staxyn? | Staxyn excipients list |
DailyMed Link: | Staxyn at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for Staxyn
Paragraph IV (Patent) Challenges for STAXYN
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
STAXYN | Orally Disintegrating Tablets | vardenafil hydrochloride | 10 mg | 200179 | 1 | 2011-12-22 |
US Patents and Regulatory Information for Staxyn
Staxyn is protected by one US patents.
Patents protecting Staxyn
Pharmaceutical forms with improved pharmacokinetic properties
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Staxyn
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Bayer Hlthcare | STAXYN | vardenafil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 200179-001 | Jun 17, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Staxyn
See the table below for patents covering Staxyn around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2260593 | 2-ФЕНИЛЗАМЕЩЕННЫЕ ИМИДАЗОТРИАЗИНОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ОБЛАДАЮЩАЯ СВОЙСТВАМИ ИНГИБИТОРА ФОСФОДИЭСТЕРАЗЫI,II И V (2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONES, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF ELICITING PROPERTY OF PHOSPHODIESTERASE I, II AND V INHIBITOR) | ⤷ Try a Trial |
Estonia | 04781 | 2-fenüülasendatud imidasotriasinoonid kui fosfodiesteraasi inhibiitorid ja nende valmistamismeetod | ⤷ Try a Trial |
Austria | 213246 | ⤷ Try a Trial | |
Costa Rica | 9339 | FORMAS FARMACEUTICAS CON PROPIEDADES FARMACOCINETICAS MEJORADAS | ⤷ Try a Trial |
China | 102198140 | Pharmaceutical forms with improved pharmacokinetic properties | ⤷ Try a Trial |
Poland | 340400 | ⤷ Try a Trial | |
Portugal | 1858490 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |